Cyclo Therapeutics has shared topline results from its Phase 3 TransportNPC study, which included Australian participants. While the study’s main endpoint was not statistically significant, important findings—including a reported survival benefit for children with infantile-onset NPC—warrant close attention and further review.

The Childhood Dementia Initiative (CDI) has made significant progress in 2023, thanks to the dedication of its partners and supporters....

Dementia-CONNECT: Connecting the dots in Childhood Dementia disorders Researchers at The Sydney Children’s Hospital Network (SCHN) are...